166 related articles for article (PubMed ID: 32334191)
1. Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1.
Yang Y; Pannecouque C; Clercq E; Zhuang C; Chen FE
Bioorg Chem; 2020 Jun; 99():103825. PubMed ID: 32334191
[TBL] [Abstract][Full Text] [Related]
2. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
Sang Y; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
Eur J Med Chem; 2019 Nov; 182():111603. PubMed ID: 31421633
[TBL] [Abstract][Full Text] [Related]
3. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
[TBL] [Abstract][Full Text] [Related]
4. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
[TBL] [Abstract][Full Text] [Related]
5. Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
Eur J Med Chem; 2020 Jan; 185():111874. PubMed ID: 31735575
[TBL] [Abstract][Full Text] [Related]
6. A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
Gu SX; Qiao H; Zhu YY; Shu QC; Liu H; Ju XL; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2015 Oct; 23(20):6587-93. PubMed ID: 26385446
[TBL] [Abstract][Full Text] [Related]
7. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
[TBL] [Abstract][Full Text] [Related]
9. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
[TBL] [Abstract][Full Text] [Related]
11. Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains.
Sang Y; Han S; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
Bioorg Chem; 2019 Aug; 89():102974. PubMed ID: 31102693
[TBL] [Abstract][Full Text] [Related]
12. Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
Ding L; Pannecouque C; De Clercq E; Zhuang C; Chen FE
J Med Chem; 2021 Jul; 64(14):10297-10311. PubMed ID: 34197708
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP.
Zhang T; Zhou Z; Zalloum WA; Wang Z; Fu Z; Cherukupalli S; Feng D; Sun Y; Gao S; De Clercq E; Pannecouque C; Kang D; Zhan P; Liu X
Bioorg Chem; 2021 Nov; 116():105353. PubMed ID: 34536931
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
Gao P; Song S; Wang Z; Sun L; Zhang J; Pannecouque C; De Clercq E; Zhan P; Liu X
Bioorg Med Chem; 2021 Jun; 40():116195. PubMed ID: 33979774
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility.
Wang JS; Zhao KX; Zhang K; Pannecouque C; De Clercq E; Wang S; Chen FE
Bioorg Chem; 2024 Jun; 147():107340. PubMed ID: 38593532
[TBL] [Abstract][Full Text] [Related]
16. Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
Jin X; Piao HR; Pannecouque C; De Clercq E; Zhuang C; Chen FE
Eur J Med Chem; 2021 Dec; 226():113868. PubMed ID: 34583311
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
Ding L; Pannecouque C; De Clercq E; Zhuang C; Chen FE
J Med Chem; 2022 Feb; 65(3):2122-2138. PubMed ID: 35073089
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Yan ZH; Wu HQ; Chen WX; Wu Y; Piao HR; He QQ; Chen FE; De Clercq E; Pannecouque C
Bioorg Med Chem; 2014 Jun; 22(12):3220-6. PubMed ID: 24794751
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
[TBL] [Abstract][Full Text] [Related]
20. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
